UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1357-5
Program Prior Authorization/Notification
Medication Fotivda® (tivozanib)
P&T Approval Date 5/2021, 5/2022, 5/2023, 5/2024, 5/2025
Effective Date 8/1/2025
1. Background:
Fotivda (tivozanib) is a kinase inhibitor indicated for the treatment of adult patients with relapsed
or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic
therapies.
Coverage Information:
Members will be required to meet the criteria below for coverage. For members under the age of
19 years, the prescription will automatically process without a coverage review.
Some states mandate benefit coverage for off-label use of medications for some diagnoses or
under some circumstances. Some states also mandate usage of other Compendium references.
Where such mandates apply, they supersede language in the benefit document or in the
notification criteria.
2. Coverage Criteriaa:
A. Patients less than 19 years of age
1. Fotivda will be approved based on the following criterion:
a. Patient is less than 19 years of age
Authorization will be issued for 12 months.
B. Renal Cell Carcinoma (RCC)
1. Initial Authorization
a. Fotivda will be approved based on all of the following criteria:
(1) Diagnosis of advanced renal cell carcinoma (RCC)
-AND-
(2) One of the following:
(a) Disease has relapsed
(b) Disease is refractory
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
(3) Patient has received two or more prior systemic therapies
Authorization will be issued for 12 months.
2. Reauthorization
a. Fotivda will be approved based on the following criterion:
(1) Patient does not show evidence of progressive disease while on Fotivda therapy
Authorization will be issued for 12 months.
C. NCCN Recommended Regimens
The drug has been recognized for treatment of the cancer indication by The National
Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium with a Category
of Evidence and Consensus of 1, 2A, or 2B
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-10)
and/or claim logic. Use of automated approval and re-approval processes varies by program
and/or therapeutic class.
• Supply limit may be in place.
4. References:
1. Fotivda [package insert]. Boston, MA: AVEO Pharmaceuticals, Inc.; August 2024.
2. The NCCN Drugs and Biologics Compendium (NCCN Compendium™). Available at
http://www.nccn.org/professionals/drug_compendium/content/contents.asp. Accessed April
9, 2025.
Program Prior Authorization/Notification - Fotivda (tivozanib)
Change Control
5/2021 New program.
5/2022 Annual review with no change to clinical criteria. Updated references.
5/2023 Annual review with no change to clinical criteria. Added state mandate
footnote. Updated reference.
5/2024 Annual review with no change to clinical criteria. Updated references.
© 2025 UnitedHealthcare Services, Inc.
2
5/2025 Annual review with no change to clinical criteria. Updated references.
© 2025 UnitedHealthcare Services, Inc.
3